Why Norway Does Not Have a Pharmaceutical Royalty Fund Yet

The Trigger

On April 16, 2026, I attended the 7th Norwegian Life Science Investor Partnering Day at Oslo Science Park. The organisers' framing was direct: Norway has world-class research, yet venture capital per capita is the lowest in the Nordics.

Between 1:1 meetings, one thing stood out. Nobody in the room was discussing royalty financing as a Norwegian product.

The Nordic sector has pension capital, insurance capital, and petroleum-finance structuring expertise that is directly transferable. It does not have a domestic royalty fund, and nobody is building one.

This article sketches what that opening looks like for practitioners who would actually need to structure it — Norwegian corporate and tax lawyers, AIFM counsel, pension and insurance investment teams, and Finanstilsynet-facing fund formation specialists — using Canada as the reference case.

The Canadian reference, in brief

Canada is the one jurisdiction that cleanly exported royalty expertise from one sector into another. The mining templates (Franco-Nevada and Wheaton Precious Metals) were built first; the pharmaceutical royalty structures came later, using almost identical covenant architectures. What transferred into pharmaceuticals was contracts and vehicles, not people.

The listed Canadian templates

A mining stream and a pharmaceutical synthetic royalty are structurally the same instrument. For Norwegian counsel drafting a deal, the covenant libraries read almost identically.

The Canadian pension-insurance loop

The mechanism Norway should study most carefully is not the streamers. It is how Canadian pension and insurance capital assembled a domestic royalty ecosystem. CPP Investments (C$777.5 billion net assets as of 30 September 2025) built the most documented direct pharmaceutical royalty programme of any global pension fund.

Three anchor transactions trace the learning curve:

All three were executed out of CPPIB's Credit Investments group — treated as credit-like assets with long duration, not as equity. That framing matters: it is the framing a Norwegian insurance investment committee or pension investment desk can most easily digest.

The insurance side of the loop closed in late 2021. Great-West Lifeco (the Power Corp insurance arm) made a capital commitment of approximately US$500 million into Sagard strategies broadly, coinciding with acquiring a minority stake in Sagard Holdings Management (Lifeco press release, 19 November 2021). Sagard Healthcare Royalty Partners sits within that multi-strategy platform. The precise allocation to the healthcare royalty strategy is not publicly disclosed, but the structural signal is clear: insurance float became the LP base for a Canadian healthcare royalty manager.

The loop: pension LP → insurance float → domestic manager → Canadian banks underwriting the listings. Norway has all four ingredients. It has not assembled them.

The 2025 internalisation wave — a sequencing lesson

For any Norwegian listed vehicle designed from today, the most relevant recent Canadian (and cross-border) signal is the wave of manager internalisations in 2025:

Both transactions cite the same rationale: the externally managed structure is an impediment to institutional ownership, and integrated governance is increasingly the precondition for serious pension and insurance LP participation at scale.

The practical implication for Norwegian counsel: a Norwegian listed royalty vehicle should be structured from day one as integrated with the manager, not as an externally managed vehicle that will later require a costly carve-in. The template has been publicly rewritten in 2025; it should not need to be relearned at Norwegian shareholder expense.

What Norway already has

Capital pools

The insurance float inside KLP and Storebrand is the single most natural Norwegian analog to the Great-West Lifeco anchor role. NBIM is not the right starting point: its mandate architecture is designed around listed securities, and royalty origination does not fit.

Petroleum finance as transferable expertise

The State owns 67% of Equinor and holds direct interests via Petoro in 187 production licences. The petroleum tax regime applies a marginal rate of 78%. Exploration costs are immediately deductible in the special tax base, and tax losses are refunded annually in cash by the State — and are pledgeable as collateral.

This produced specialised Norwegian expertise in structuring cash-flow-backed, non-recourse instruments against state-recognised credits. Petroleum project finance lawyers at BAHR, Thommessen, Wikborg Rein, and Schjødt already draft non-recourse cash-flow instruments that are structurally identical to the volumetric production payments (VPPs) underpinning pharmaceutical synthetic royalties.

The reskilling distance from petroleum VPP covenants to biopharma royalty covenants is months, not years. A Norwegian counsel who has papered a farm-out with carried-interest mechanics, or structured a tax-loss-backed exploration financing, already knows the conceptual toolkit.

The biotech origination base

The 2026 Partnering Day showed Norwegian biotech origination thickening, with companies at various stages of licensing, partnering, and platform commercialisation. Absolute deal volume still sits well below Boston or the UK Golden Triangle.

Any Norwegian royalty fund would — like BioPharma Credit plc from the LSE — need to source globally. Domestic origination is a pipeline contributor, not a franchise foundation. That is the right expectation to set with Norwegian LPs from the outset.

The Norwegian tax framework for royalties

This is the area most often misunderstood in Norwegian fund formation conversations. Three layers need to be worked through separately.

Layer 1: Norwegian CIT on royalty receipts

A Norwegian resident company is taxed on worldwide income at 22% ordinary CIT (25% for financial sector entities). Royalty income is taxable on an accrual basis.

There is no Norwegian equivalent of an Irish Knowledge Development Box or a Swiss patent box. No reduced rate applies to royalty income specifically. A Norwegian royalty fund holding royalties directly on its balance sheet would simply be taxed at 22% on its royalty receipts, the same as any other corporate income.

Layer 2: Norwegian WHT on outbound royalties

Norway introduced a 15% withholding tax on cross-border royalty payments effective 1 July 2021 (DLA Piper summary; PwC Norway corporate WHT; BDO Norway WHT note).

Key parameters:

For a Norwegian royalty fund paying outbound royalties, this is relevant when structuring licence agreements that pass IP rights through related-party chains. It is less commonly engaged for a royalty fund whose business is receiving royalties.

Layer 3: NOKUS (CFC) rules

If Norwegian tax residents hold 50%+ of a foreign entity in a low-tax jurisdiction (same two-thirds threshold), the entity is treated as a NOKUS and its profits are taxed on the Norwegian shareholders as if distributed. Exit tax applies to assets leaving the Norwegian tax area.

What this actually means for a Norwegian royalty fund

The practical implication is clearer than it first appears:

• The low-tax test is only triggered if the fund routes royalty receipts through a haven holding structure.
• For pharmaceutical royalties, haven holding is rarely the natural architecture. Most pharmaceutical royalties sit on US or EU-origin drugs; the underlying IP is already held by US, Swiss, or Irish operators.
• A Norwegian fund buying a royalty on a US-origin drug typically does not need to park the royalty interest offshore at all. It can hold the royalty directly, or through a US (21% federal CIT) or Irish (12.5% CIT) vehicle — both above the 14.67% low-tax floor — and accept 22% Norwegian CIT on its share of receipts.

That is not tax-optimal relative to a pure Luxembourg or Guernsey fund wrapper, but it is not structurally disqualifying either.

Could Norway create a bespoke pass-through regime?

The closest Norwegian precedent is the Norwegian tonnage tax, introduced in 1996 and re-approved by the EFTA Surveillance Authority in December 2017 for another ten years. It covers roughly 750 shipping companies under a daily per-ton levy in lieu of ordinary corporation tax.

Whether ESA would approve an analogous framework for pharmaceutical royalty vehicles is untested. The procedural template for requesting it exists. The political weight currently does not.

Fund structure — and the true-sale question

A Norwegian royalty fund is unlikely to hold royalty interests directly on the Norwegian fund balance sheet. This is not a tax-avoidance point. It is how every comparable fund is built internationally.

The Royalty Pharma architecture as a reference

Before May 2025, RP Management received quarterly fees equal to 6.5% of Portfolio Receipts and 0.25% of the value of security investments. That fee layer has now been collapsed into the listed parent. The sub-trust structure (RPIFT / RPCT / RPI Acquisitions Ireland) remains.

The European private fund toolkit

Private royalty and royalty-adjacent funds typically use one of the following:

Blackstone Life Sciences V (US$5.05B at final close) uses Delaware and Luxembourg parallel vehicles. Sagard Healthcare Royalty Partners is an LP structure.

A workable Norwegian stack

The Norwegian element provides the manager and LP anchor. The holding-level domicile is selected for portfolio-company tax efficiency, not for Norwegian tax optimisation:

Fund level. Norwegian AIF as a limited partnership under the Partnership Act (selskapsloven), authorised or registered with Finanstilsynet under the Norwegian AIFM Act (AIF-loven). For non-EEA LPs, a parallel Luxembourg SCSp/RAIF or Irish ILP feeder is conventional.

Holding level. US-origin royalties in a Delaware statutory trust or Delaware LLC, mirroring RPIFT. EU-origin royalties in an Irish holdco (12.5% CIT, 75+ treaty network — the same reason Royalty Pharma uses Ireland).

Neither Delaware nor Ireland is a low-tax jurisdiction under the Norwegian two-thirds test (Delaware federal CIT 21%, Ireland 12.5%, both above the 14.67% floor). The NOKUS/CFC rules therefore do not attribute phantom income to Norwegian investors.

Manager level. Norwegian AIFM authorised by Finanstilsynet, in Oslo. Given the 2025 internalisation wave at Royalty Pharma and DRI, the manager should be structured from inception as integrated with the fund entity, not as a separately owned external advisor. The externally managed template is now a known, priced-in liability.

This resolves the Norwegian tax question almost automatically. The 22% CIT falls only on the Norwegian management vehicle's fees and carried interest (or, for an integrated structure, on the integrated manager's margin) — not on the underlying royalty receipts, which are earned in the jurisdiction of the sub-holding and can flow up to the Norwegian fund level under the participation exemption (fritaksmetoden) for qualifying shareholdings in EEA and non-low-tax jurisdictions.

The true-sale versus loan question

This is the single most technical point in royalty deal documentation. It matters for Norwegian counsel for two specific reasons.

A pharmaceutical royalty transaction can be structured as either:

The economic cash flows can look identical in the first several years. The legal and tax consequences diverge significantly.

The RSM analysis of royalty monetisation notes that pharmaceutical royalty monetisations are often treated as sales rather than loans for US federal income tax purposes, but each deal turns on specific facts: caps, put rights, top-up payments, recourse features, or guaranteed minimum returns all push toward loan characterisation. Covington & Burling's 2022 guide to synthetic drug royalty dealmaking makes the same point from the seller side. Gibson Dunn's 2024 Law360 article tracks 350% year-over-year growth in synthetic royalty transactions post-2020 and highlights the Article 9 UCC filings now standard on US-structured deals.

Why this matters for a Norwegian fund:

1. At the sub-holding level. True-sale structuring ensures the royalty interest is treated as a capital asset held by the Delaware or Irish vehicle, not as a loan receivable. That matters for non-recourse treatment, bankruptcy remoteness (if the underlying biotech fails), and consolidating portfolio cash flows at the fund level without debt-style accounting.
2. At the Norwegian level. The legal form determines whether the Norwegian fund receives royalty income (ordinary CIT at the sub-holding, dividend up to the Norwegian fund under the participation exemption for qualifying shareholdings) or interest income (different treatment, potentially different WHT considerations). The participation exemption covers dividends and capital gains on qualifying shares in EEA and non-low-tax jurisdictions — another reason the Delaware/Ireland sub-holding stack works smoothly for a Norwegian parent fund.

The Norwegian fund is not designing anything novel. The standard international toolkit solves most of the tax and structural questions. The Norwegian innovation sits in the manager, the LP anchor, and the deal origination — not in the holding structure.

Listing and sequencing

The domestic listing question

The structural end-state that would most closely mirror a TSX-listed royalty vehicle (DRI Healthcare Trust, now internally managed after July 2025) or an LSE-listed royalty-backed credit vehicle (BioPharma Credit plc) is a listed Norwegian investment company.

Two practical constraints apply:

• As of early 2026 there are no listed AIFs in Norway.
• Oslo Børs rules restrict exchange-traded funds to UCITS or funds investing only in instruments traded on a regulated market.

Three workable options:

Sequencing

The Canadian precedent is specific: pension and insurance LPs participate as fund investors before domestic direct activity emerges.

• CPPIB committed capital to royalty managers before writing direct cheques — eight years passed between its first external commitments and the Keytruda direct buy.
• Great-West Lifeco anchored Sagard before Sagard had a track record.
• Pharmakon built BioPharma Credit plc after a decade of private fund management.

Origination is the slowest piece. None of the large royalty players reached consistent lead-investor status in less than a decade.

The 2025 internalisation wave adds a further sequencing note: a Norwegian listed vehicle launched today should be built as integrated from inception. The alternative path (external manager first, internalise later) now carries a known, priced-in transaction cost.

What would need to happen

1. A Norwegian anchor LP. Most plausibly KLP or Storebrand insurance float, or a consortium including DNB Carnegie, willing to seed a first-time domestic manager.
2. A specialist royalty fund management team. Combining petroleum-finance structuring experience from the Norwegian legal bench (BAHR, Thommessen, Wikborg Rein, Schjødt) with scientific and commercial diligence capability imported from existing global managers.
3. A clear regulatory path. AIF-first under Finanstilsynet authorisation, with a listed ASA or Euronext Growth Oslo vehicle as the medium-term endpoint. Built as an integrated manager-and-vehicle structure from day one.
4. A global origination footprint. Norwegian biotech is a pipeline contributor, not a foundation. This is true of every European royalty manager today.
5. Optional longer-term step. An ESA state aid submission for a sector-specific pass-through regime modelled on the tonnage tax. Years-long process with uncertain outcome; probably not on the critical path.

Conclusion

Norway has the capital pools, the tax-credit structuring heritage, the legal bench, and a growing biotech origination base. The Norwegian royalty tax framework is workable rather than hostile, provided the fund is structured around royalties on internationally originated IP rather than Norwegian-controlled IP parked offshore.

What is missing is a listed vehicle, an embedded scientific diligence function, and a pension or insurance anchor LP willing to seed a first-time Norwegian royalty manager.

The Canadian transition took roughly 25 years. A Norwegian equivalent would not need to take that long. Most of the required infrastructure already exists — in Oslo, Stavanger, Toronto, London, and Zurich — and the governance template has now been publicly rewritten in 2025 by Royalty Pharma and DRI. The manager should be integrated from inception. The holding stack already has a standard form. The tax questions have known answers.

Whether the country assembles it, and in what form, is a separate question. The 7th Partnering Day was not where that question was answered. The 8th, perhaps, could be.

All information in this article was accurate as of the publication date and is derived from publicly available sources including company press releases, SEC filings, regulatory announcements, and financial news reporting. Information may have changed since publication. This content is for informational purposes only and does not constitute investment, legal, or financial advice. The author is not a lawyer or financial adviser.